Results 1 to 10 of about 6,730 (183)
The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience [PDF]
Vojnosanitetski Pregled, 2022 Background/Aim. The availability of thrombopoietin receptor agonists (TPO-RA) for treating primary immune thrombocytopenia (ITP) has transformed its management over the last decade.
Virijević Marijana +5 more
doaj +1 more source
In and out: Traffic and dynamics of thrombopoietin receptor [PDF]
Journal of Cellular and Molecular Medicine, 2021 AbstractThrombopoiesis had long been a challenging area of study due to the rarity of megakaryocyte precursors in the bone marrow and the incomplete understanding of its regulatory cytokines. A breakthrough was achieved in the early 1990s with the discovery of the thrombopoietin receptor (TpoR) and its ligand thrombopoietin (TPO).
Anita Roy +2 more
openaire +2 more sources
Frontiers in Pharmacology, 2022 Objective: To explore the effect and safety of avatrombopag for chemotherapy-induced thrombocytopenia (CIT).Methods: This multicenter, open-label, single-arm trial enrolled CIT patients in eight centers from October 2020 to April 2021.
Yayun Cui +10 more
doaj +1 more source
Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments
HemaSphere, 2021 Immune thrombocytopenia (ITP) is a rare autoimmune disease due to both a peripheral destruction of platelets and an inappropriate bone marrow production.
Sylvain Audia +5 more
doaj +1 more source
Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern
Research and Practice in Thrombosis and Haemostasis, 2021 Corticosteroids remain a crucial component of first‐line therapy for immune thrombocytopenia (ITP) due to low cost, high initial response rates, and acceptable short‐term tolerability.
Adam Cuker, Howard A. Liebman
doaj +1 more source
The regulation of platelet production and therapeutic drugs
生物医学转化, 2021 Platelets are essential blood cells for maintaining hemostasis. Thrombocytopenia and thrombocy‐themia are common platelet-related blood diseases with serious symptom, such as bleeding and thrombosis.Thrombocytopenic arrest and the abnormal clearance of ...
Xu Yanyan, Jiang Haojie, Liu Junling
doaj +1 more source
Peptide agonists of the thrombopoietin receptor [PDF]
Stem Cells, 1998 We have screened a variety of L-amino acid peptide libraries against the extracellular domain of the human thrombopoietin (HuTPO) receptor, c-Mpl. A large number of peptide ligands were recovered and categorized into two families. Peptides from each family compete with the binding of HuTPO and with the binding of peptides from the other familiy ...
W J, Dower +5 more
openaire +2 more sources
Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia [PDF]
British Journal of Haematology, 2018 SummaryAutoantibodies to thrombopoietin (TPO, also termed THPO) or the TPO receptor (cMpl, also termed MPL) could play a pathological role in immune thrombocytopenia (ITP). In this study, we tested for autoantibodies against TPO, cMpl, or the TPO/cMpl complex in ITP and other thrombocytopenic disorders. Using an inhibition step with excess TPO in fluid‐
Ishac Nazy +9 more
openaire +2 more sources
Iatreia, 2021 Introduction: Immune thrombocytopenia is a frequent hematologic manifestation in systemic lupus erythematosus (SLE). Corticosteroids are the first line of treatment for moderate to severe thrombocytopenia in this disease, in conjunction with ...
Toro Vélez, Esteban +2 more
doaj +1 more source
Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice [PDF]
Терапевтический архив, 2018 Objective: To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP in real-world clinical practice. Materials and methods.The article contains long-term results analysis of ATR application under real clinical ...
V V PTUSHKIN +5 more
doaj +1 more source